Get the Stockscreener App
136.01
0.47%
-0.64
Jazz Pharmaceuticals Plc stock is traded at $136.01, with a volume of 542.46K.
It is down -0.47% in the last 24 hours and up +12.01% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$136.65
Open:
$137.37
24h Volume:
542.46K
Relative Volume:
0.92
Market Cap:
$8.22B
Revenue:
$3.99B
Net Income/Loss:
$463.16M
P/E Ratio:
19.16
EPS:
7.1
Net Cash Flow:
$1.10B
1W Performance:
+1.53%
1M Performance:
+12.01%
6M Performance:
+18.93%
1Y Performance:
+5.91%
1-Day Range:
$134.58
$137.60
1-Week Range:
$132.58
$137.60
52-Week Range:
$99.06
$138.27
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
136.01 | 8.22B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
First Week of April 17th Options Trading For Jazz Pharmaceuticals - Nasdaq
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Venturi Wealth Management LLC - MarketBeat
Van ECK Associates Corp Reduces Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Can Jazz Pharmaceuticals' Next Strategic Move Transform Its $2B Portfolio? Key Insights Coming - StockTitan
Jazz (JAZZ) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures - Yahoo Finance
Autism Spectrum Disorder Treatment Market Size is expected - openPR
Convergence Investment Partners LLC Makes New Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Philip James Wealth Mangement LLC Has $1.31 Million Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals (JAZZ) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) Hits New 1-Year HighStill a Buy? - MarketBeat
JP Morgan 2025: Jazz Pharmaceuticals focusing on oncology pipeline - MSN
Jazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded at Wells Fargo & Company - MarketBeat
Summit Trail Advisors LLC Takes $539,000 Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Warther Private Wealth LLC Sells 31,065 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) Shares Up 6.2%What's Next? - MarketBeat
Harvey Capital Management Inc. Purchases Shares of 25,450 Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Moloney Securities Asset Management LLC Takes $464,000 Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Polaris Capital Management LLC Reduces Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals stock hits 52-week high of $134.24 By Investing.com - Investing.com Australia
Lewy Body Dementia Pipeline 2025: FDA Approvals and Clinical - openPR
Wells Fargo Upgrades Jazz Pharmaceuticals to Overweight From Equalweight, Adjusts Price Target to $170 From $130 - Marketscreener.com
Wells Fargo Upgrades Jazz Pharmaceuticals (BRSE:J7Z) - Nasdaq
This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Wells Fargo Upgrades Jazz Pharmaceuticals (JAZZ) - Nasdaq
Deep Dive Into Jazz Pharmaceuticals Stock: Analyst Perspectives (9 Ratings) - Benzinga
Jazz Pharmaceuticals stock hits 52-week high of $134.24 - MSN
Jazz (JAZZ) Surges 5.2%: Is This an Indication of Further Gains? - Nasdaq
Graphene Investments SAS Cuts Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025 - ShareCast
Jazz Pharmaceutical wraps up Epidiolex patent claims - Green Market Report
Jazz Pharma Drops Last Defendant From Epidiolex Patent Suit - Law360
Avadel Pharmaceuticals gains as holder pushes for sale process (AVDL:NASDAQ) - Seeking Alpha
ASL Strategic Value Fund Letter to Avadel Pharmaceuticals (AVDL: NASDAQ) Board of Directors - Yahoo Finance
Meritage Portfolio Management Has $8.16 Million Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd Sells 1,500 Shares of Stock - MarketBeat
Fed Circ. Considers Some Testing For Avadel Sleep Drug - Law360
Jazz Pharmaceuticals: Turning the Tables on Cancer with The - CSRwire.com
Jazz Pharmaceuticals Joins the Movement for Awareness and Suppor - GuruFocus.com
Jazz Pharmaceuticals Joins the Movement for Awareness and Support on World Cancer Day with The Upside Down Challenge - StreetInsider.com
Jazz Pharmaceuticals CEO Bruce Cozadd sells shares worth $183,465 - MSN
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Sees Large Decrease in Short Interest - MarketBeat
Institute for Wealth Management LLC. Makes New $260,000 Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):